The Association of Pioglitazone and Urinary Tract Disease in Type 2 Diabetic Taiwanese: Bladder Cancer and Chronic Kidney Disease
Open Access
- 10 January 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e85479
Abstract
Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified. The aim of this study was to investigate the factors that may link pioglitazone to bladder cancer. In total, 34,970 study subjects were identified from the National Health Insurance Research Database in 2003 with follow-up from 2005 to 2009. The demographic characteristics of patients who had used and had never used pioglitazone, including age, sex, diabetes duration, urinary tract disease, nephropathy, bladder cancer, and cumulative dose and duration of pioglitazone therapy, were analyzed using the χ2 test. Cox proportional hazard regression models were used to determine the independent effects of pioglitazone on bladder cancer and newly developed chronic kidney disease. Among 3,497 ever users and 31,473 never users of pioglitazone, the respective incident cases of bladder cancer were 12 (0.4%) and 72 (0.2%), and for newly developed chronic kidney disease 245 (8.1%) and 663 (2.3%), respectively. Ever use of pioglitazone [1.59(1.32–1.91)], cumulative dose of pioglitazone 10,500 mg [1.34 (1.04–1.73)], and duration of therapy 12 months [1.39 (1.09–1.76)] were associated with the development of chronic kidney disease. There was no association of pioglitazone use with bladder cancer development, however, there was an association with an increased risk of newly developed chronic kidney disease.Keywords
This publication has 37 references indexed in Scilit:
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort studyDiabetologia, 2012
- Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event ReportingDiabetes Care, 2011
- Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneDiabetes Care, 2011
- Association of CKD and Cancer Risk in Older PeopleJournal of the American Society of Nephrology, 2009
- Association of Albuminuria and Cancer IncidenceJournal of the American Society of Nephrology, 2008
- Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2008
- The Role of PPARs in CancerPPAR Research, 2008
- Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Biomarkers of inflammation and progression of chronickidney diseaseKidney International, 2005
- Inflammation and cancerNature, 2002